Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Inovio Pharmaceuticals Inc — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.47, while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: VanEck JP Morgan EM Local Currency Bond ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EMLC | INO | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $2.87 |
52-Week Low | $24.83 | $1.05 |
Market Cap | — | $96.26M |
Enterprise Value | — | $67.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.47 with minimal daily movement (-0.06%). Technical indicators show a bullish trend with moving averages supporting upward momentum, though oscillators remain neutral. The ETF maintains consistent dividend payments of $0.14 per share quarterly, providing income stability. Recent news highlights growing institutional interest in emerging market debt as investors seek yield above Treasury bonds.
The outlook remains positive given the 6.1% yield advantage over Treasuries, though currency risk and capital erosion concerns persist. Short interest has surged 73% recently, indicating some skepticism about sustainability. Federal Reserve policy decisions will be crucial for EM debt performance through 2026.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
